What is Zacks Research's Forecast for AGIO FY2025 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Research analysts at Zacks Research dropped their FY2025 earnings per share estimates for shares of Agios Pharmaceuticals in a report issued on Thursday, July 10th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn ($7.28) per share for the year, down from their previous estimate of ($7.27). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals' Q4 2025 earnings at ($2.07) EPS, Q4 2026 earnings at ($1.97) EPS, Q1 2027 earnings at ($1.64) EPS, Q2 2027 earnings at ($1.71) EPS and FY2027 earnings at ($6.83) EPS.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Scotiabank cut their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $58.60.

Agios Pharmaceuticals Trading Up 0.5%

Shares of AGIO traded up $0.18 during midday trading on Monday, hitting $39.23. 702,549 shares of the company's stock traded hands, compared to its average volume of 667,619. Agios Pharmaceuticals has a 1 year low of $23.42 and a 1 year high of $62.58. The firm's fifty day moving average is $32.72 and its 200-day moving average is $32.02. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of 3.49 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 18,700 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the sale, the chief executive officer directly owned 105,401 shares of the company's stock, valued at approximately $3,535,149.54. This trade represents a 15.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tsveta Milanova sold 2,770 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the sale, the insider directly owned 26,122 shares in the company, valued at $876,131.88. This represents a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,963 shares of company stock worth $1,563,654 in the last three months. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. grew its position in shares of Agios Pharmaceuticals by 3.6% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 37,024 shares of the biopharmaceutical company's stock valued at $1,231,000 after acquiring an additional 1,295 shares during the period. Strs Ohio acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at about $240,000. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at about $133,000. SCS Capital Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at about $17,905,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Agios Pharmaceuticals by 19.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 147,276 shares of the biopharmaceutical company's stock valued at $4,315,000 after acquiring an additional 24,441 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.